Literature DB >> 9160688

Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro.

J L Schultze1, M J Seamon, S Michalak, J G Gribben, L M Nadler.   

Abstract

Follicular lymphomas (FLs) rarely induce clinically significant T-cell-mediated responses. We showed that freshly isolated tumor infiltrating T cells (T-TILs) lack tumor-specific cytotoxicity. Stimulation of these T cells with FL cells in the presence of interleukin-2 (IL-2) and/or costimulation via CD28 does not lead to T-cell activation and expansion. In contrast, when stimulated with FL cells preactivated via CD40, autologous T-TILs can be expanded by the addition of exogenous IL-2. These T cells can be further expanded in vitro by the addition of exogenous IL-4, IL-7, or interferon-gamma, but not IL-12. Once activated, these T cells showed FL-directed cytotoxicity in four of five patients tested. We concluded that autologous cytotoxic anti-FL-specific T cells exist, but can only be detected in vitro under optimized conditions for T-cell stimulation and expansion. This suggests that their frequency in vivo is either very low or that the microenvironment does not provide the necessary signals to activate these T cells. This model system allows dissection of the requisite conditions for activation and expansion of lymphoma-directed cytotoxicity and may permit expansion of previously activated cytotoxic T cells for adoptive transfer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9160688

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

Review 1.  Biotherapy for lymphoma.

Authors:  P McLaughlin
Journal:  Curr Oncol Rep       Date:  2000-03       Impact factor: 5.075

2.  Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells.

Authors:  K Kato; M J Cantwell; S Sharma; T J Kipps
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

3.  Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.

Authors:  Jason R Westin; Fuliang Chu; Min Zhang; Luis E Fayad; Larry W Kwak; Nathan Fowler; Jorge Romaguera; Fredrick Hagemeister; Michelle Fanale; Felipe Samaniego; Lei Feng; Veerabhadran Baladandayuthapani; Zhiqiang Wang; Wencai Ma; Yanli Gao; Michael Wallace; Luis M Vence; Laszlo Radvanyi; Tariq Muzzafar; Rinat Rotem-Yehudar; R Eric Davis; Sattva S Neelapu
Journal:  Lancet Oncol       Date:  2013-12-11       Impact factor: 41.316

4.  Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model.

Authors:  Baochun Zhang; Sven Kracker; Tomoharu Yasuda; Stefano Casola; Matthew Vanneman; Cornelia Hömig-Hölzel; Zhe Wang; Emmanuel Derudder; Shuang Li; Tirtha Chakraborty; Shane E Cotter; Shohei Koyama; Treeve Currie; Gordon J Freeman; Jeffery L Kutok; Scott J Rodig; Glenn Dranoff; Klaus Rajewsky
Journal:  Cell       Date:  2012-02-17       Impact factor: 41.582

Review 5.  The follicular lymphoma microenvironment: From tumor cell to host immunity.

Authors:  Antonio Martinez; Joaquim Carreras; Elias Campo
Journal:  Curr Hematol Malig Rep       Date:  2008-10       Impact factor: 3.952

Review 6.  Vaccination strategies in follicular lymphoma.

Authors:  Shibichakravarthy Kannan; Sattva S Neelapu
Journal:  Curr Hematol Malig Rep       Date:  2009-10       Impact factor: 3.952

7.  CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.

Authors:  J L Schultze; S Michalak; M J Seamon; G Dranoff; K Jung; J Daley; J C Delgado; J G Gribben; L M Nadler
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

8.  Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition?

Authors:  Simone Kayser; Iris Watermann; Christine Rentzsch; Toni Weinschenk; Diethelm Wallwiener; Brigitte Gückel
Journal:  J Cancer Res Clin Oncol       Date:  2003-06-26       Impact factor: 4.553

9.  Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment.

Authors:  Seema Rawal; Fuliang Chu; Min Zhang; Hyun Jun Park; Durga Nattamai; Shibichakravarthy Kannan; Rakesh Sharma; David Delgado; Tina Chou; Heather Y Lin; Veerabhadran Baladandayuthapani; Amber Luong; Francisco Vega; Nathan Fowler; Chen Dong; R Eric Davis; Sattva S Neelapu
Journal:  J Immunol       Date:  2013-05-17       Impact factor: 5.422

10.  Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy.

Authors:  M Wang; L Sun; J Qian; X Han; L Zhang; P Lin; Z Cai; Q Yi
Journal:  Leukemia       Date:  2009-02-19       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.